Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' ...

Scientists reprogrammed a woman's fat cells to become insulin-making beta cells, reversing her type 1 diabetes.

A collaboration of researchers led by Emory University Rollins School of Public Health, Atlanta, is urging caution when ...

CHICAGO (CBS) – A groundbreaking treatment for type 1 diabetes is showing promising results for patients in Chicago. It's a ...

A newly designed therapy following an islet cell transplant could mean people with type 1 diabetes no longer need to inject ...

"It is crucial to consider the off-label status of these medications and the associated safety concerns in the type 1 diabetes population before prescribing them," Shao told MedPage Today ...

Off-label SGLT2 inhibitors increase the risk of euglycemic diabetic ketoacidosis. GLP-1RAs may lead to rapid weight loss in ...

On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...

The company is also running the phase 3 PROTECT trial of teplizumab in newly diagnosed type 1 diabetes patients, in the hope of expanding the indications for the drug, and reached its target ...

Endocrinologic and Metabolic Drugs Advisory Committee, the majority of panel members voted against the approval of sotagliflozin (Zynquista™) for use as an adjunct to insulin therapy for glycemic ...

and I very much want an adjunctive drug for my patients with type 1 diabetes," said committee chair Cecilia Low Wang, MD, of the University of Colorado in Aurora. The FDA rejected sotagliflozin 5 ...